Novartis | Page 2 | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Explainer
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Monday
March 02, 2026

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Explainer
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
MONDAY, MARCH 02, 2026

Novartis

Novartis

The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020/Reuters

Novartis trims sales outlook after hit from Covid disruptions

The group's net income fell 4 percent to $1.9 billion, with sales down 1 percent at $11.35 billion for the three months to June 30

The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020/Reuters

Novartis to provide 'no profit' Covid-19 drugs to low income countries

Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017/ Reuters

Novartis faces key meeting in US bribery scandal after settling corruption case

A pharmacist displays a box of Hydroxychloroquine at the CHR Centre Hospitalier Regional de la Citadelle Hospital amid the coronavirus disease in Liege, Belgium, June16, 2020/ Reuters

Novartis halts malaria drug trial against Covid-19 amid participant shortfall

Novartis donates safety gears to combat coronavirus

Novartis donates safety gears to combat coronavirus

FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the French company's headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau

Novartis inks deal to make Mass General Brigham's Covid-19 vaccine candidate

The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020/Reuters

Novartis, US regulators agree to malaria drug trial against Covid-19

Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017/ Reuters

Malaria drug is biggest hope against coronavirus: Novartis CEO

A logo for Pfizer is displayed on a monitor on the floor at the New York Stock Exchange (NYSE) in New York, US, July 29, 2019/ Reuters

Pfizer, Novartis lead $2 billion spending spree on gene therapy production

Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker

Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker

US FDA says some data testing Novartis' $2 million gene therapy was manipulated

US FDA says some data testing Novartis' $2 million gene therapy was manipulated

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2026
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net